Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618998 | 0.93 | — | — | |
| SCHEMBL4108757 | 0.79 | — | — | |
| SCHEMBL190574 | 0.76 | MAPT (0.43) | — | |
| SCHEMBL190077 | 0.76 | MAPT (0.43) | — | |
| SCHEMBL27468130 | 0.76 | TP53 (0.33) | — | |
| SCHEMBL1668708 | 0.75 | PRKCA (0.36) | PRKCA | |
| SCHEMBL27894227 | 0.75 | PRKCA (0.32) | PRKCA | |
| SCHEMBL11433341 | 0.73 | PRKCA (0.36) | PRKCA | |
| SCHEMBL27449363 | 0.73 | MMP8 (0.33) | — | |
| SCHEMBL1591709 | 0.69 | TDP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2009002913-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | AVICENA GROUP, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1207846-B1 | TOWELETTE PRODUCT | UNILEVER PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| EP-1161518-B1 | TOWELETTE PRODUCT | UNILEVER PLC (GB) | 2006-05-31 | — | — | EP | disclosed |
| CN-1182835-C | Towelette product | — | 2005-01-05 | — | — | CN | disclosed |
| US-6767924-B2 | COMPRISES 2-KETOETHANOIC ACID FOR COSMETIC CONDITIONS AND DERMATOLOGIC DISORDERS | TRISTRATA TECHNOLOGY, INC. | 2004-07-27 | — | — | US | disclosed |
| US-20030083380-A1 | Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging | YU RUEY J (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030044362-A1 | Method and product for skin lightening | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030017130-A1 | Additives enhancing topical applications of therapeutic agents | TRISTRATA, INC. | 2003-01-23 | — | — | US | disclosed |
| CN-1378442-A | Towlette product | UNILEVER NV (NL) | 2002-11-06 | — | — | CN | disclosed |
| US-5643961-A | TREATMENT OF SKIN WITH COSMETICS | TRISTRATA TECHNOLOGY, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5643952-A | SKIN DISORDERS | TRISTRATA TECHNOLOGY, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5643963-A | AGING RESISTANCE OF SKIN BY REDUCING WRINKLES | TRISTRATA TECHNOLOGY, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5643962-A | SKIN DISORDERS | TRISTRATA TECHNOLOGY, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5637615-A | ANTIAGING AGENT | TRISTRATA TECHNOLOGY, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0671162-A2 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5385938-A | application of mixtures containing hydroxyacetic acid(or its salts) to skin | IGI, INC. | 1995-01-31 | — | — | US | disclosed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | disclosed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105196-A1 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS | CKMT1A; CKMT1B, CRAT, LRAT | PRKCA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.